2017 ACVIM Forum Research Abstract Program

Nineteen client-owned dogs who were presented to the UT-VMC internal medicine service for nasal biopsy between March 2015 and August 2016 were enrolled prospectively. Dogs were randomized to treatment (YB) or placebo control group. Owners, statisticians and primary investigators were blinded to which treatment the dog received. Each dog received 2 doses of drug, one dose at 6 pm the evening before and one dose at 6 am the morning of the procedure according to body weight. All dogs had baseline blood pressure, platelet count, prothrombin time and activated partial thromboplastin time performed at presentation and a BMBT performed before and after capsule administration. Dogs were excluded from the study if systolic blood pressure was >160 mmHg, platelet count 13 sec, PTT > 90.6 sec or BMBT > 4 minutes. In addition to BMBT, 9/19 had both TEG and blood loss measurements performed, 6/19 had only TEG performed, and 4/19 had only blood loss measurements performed. Measurements of blood loss included total blood loss, blood loss as a percentage of body weight and time to stop bleeding. A standardized anesthetic protocol was followed. A final diagnosis was determined by histopathologic evaluation of biopsy samples, CT findings and/or cytological exam on an individual case basis. Statistical analysis of blood loss measures was performed using a two-way ANCOVA. A repeated measures mixed effects ANCOVA was used to analyze BMBT and TEG variables (alpha angle, K, R, MA). Backwards variable elimination was performed to evaluate the effect of covariates. A P value < 0.05 was considered statistically significant.